NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free MRSN Stock Alerts $2.85 -0.03 (-1.04%) (As of 04:32 PM ET) Add Compare Share Share Today's Range$2.74▼$2.9150-Day Range$2.88▼$5.9452-Week Range$0.80▼$9.62Volume2.00 million shsAverage Volume2.21 million shsMarket Capitalization$345.71 millionP/E RatioN/ADividend YieldN/APrice Target$6.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mersana Therapeutics alerts: Email Address Mersana Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside121.3% Upside$6.29 Price TargetShort InterestBearish8.72% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment1.04Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector146th out of 907 stocksPharmaceutical Preparations Industry53rd out of 422 stocks 4.4 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.72% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Mersana Therapeutics has recently increased by 4.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.8 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 9.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Mersana Therapeutics Stock (NASDAQ:MRSN)Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More MRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRSN Stock News HeadlinesApril 20, 2024 | seekingalpha.comMRSN Mersana Therapeutics, Inc.April 19, 2024 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 5, 2024 | morningstar.comMersana Therapeutics Inc MRSNApril 4, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 ExpertsMarch 1, 2024 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | nasdaq.comGuggenheim Upgrades Mersana Therapeutics (MRSN)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming MilestonesMarch 1, 2024 | msn.comTruist Securities Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | msn.comWedbush Upgrades Mersana Therapeutics (MRSN)February 29, 2024 | markets.businessinsider.comExpert Outlook: Mersana Therapeutics Through The Eyes Of 5 AnalystsFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | realmoney.thestreet.comGuggenheim gets more bullish on Mersana Therapeutics, upgrades sharesFebruary 29, 2024 | finance.yahoo.comAn Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% UndervaluedFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics Full Year 2023 Earnings: Revenues DisappointFebruary 29, 2024 | finance.yahoo.comQ4 2023 Mersana Therapeutics Inc Earnings CallFebruary 28, 2024 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | msn.comMersana Therapeutics GAAP EPS of -$0.16 in-line, revenue of $10.7M misses by $4.07MFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comHere's what Wall Street expects from Mersana Therapeutics's earningsFebruary 27, 2024 | msn.comMersana Therapeutics Q4 2023 Earnings PreviewFebruary 27, 2024 | globenewswire.comMersana Therapeutics to Present at Upcoming Investor ConferencesFebruary 27, 2024 | benzinga.comMersana Therapeutics Stock (NASDAQ:MRSN) Dividends: History, Yield and DatesSee More Headlines Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees123Year FoundedN/APrice Target and Rating Average Stock Price Target$6.29 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+118.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-465.80% Pretax Margin-465.80% Return on Equity-282.36% Return on Assets-62.64% Debt Debt-to-Equity Ratio0.63 Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$36.85 million Price / Sales9.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book9.29Miscellaneous Outstanding Shares121,300,000Free Float106,140,000Market Cap$349.34 million OptionableOptionable Beta1.50 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Martin H. Huber M.D. (Age 63)President, CEO & Director Comp: $44kMr. Brian C. DeSchuytner (Age 45)Senior VP, CFO & COO Comp: $626.32kDr. Timothy B. Lowinger Ph.D. (Age 60)Senior VP and Chief Science & Technology Officer Comp: $666.3kMs. Alejandra Veronica Carvajal J.D. (Age 50)Senior VP, Secretary & Chief Legal Officer Comp: $606.51kMr. Mikhail Papisov Ph.D.Co-FounderMr. Ashish Mandelia (Age 49)VP, Controller & Chief Accounting Officer Mr. Jason FredetteSenior Vice President of Investor Relations & Corporate CommunicationsMr. Chuck MillerSenior Vice President of Regulatory AffairsMr. Marc DamelinExe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.Dr. Tushar Misra Ph.D. (Age 63)Senior VP & Chief Manufacturing Officer Comp: $485.89kMore ExecutivesKey CompetitorsHeron TherapeuticsNASDAQ:HRTXOrganogenesisNASDAQ:ORGOBiomea FusionNASDAQ:BMEAEsperion TherapeuticsNASDAQ:ESPRCorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInsiders & InstitutionsHunter Perkins Capital Management LLCSold 10,700 shares on 4/23/2024Ownership: 0.012%Readystate Asset Management LPBought 295,038 shares on 2/20/2024Ownership: 0.244%Affinity Asset Advisors LLCSold 1,850,000 shares on 2/13/2024Ownership: 0.828%Tower Research Capital LLC TRC Sold 23,776 shares on 2/13/2024Ownership: 0.020%Foundations Investment Advisors LLCBought 102,000 shares on 2/8/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions MRSN Stock Analysis - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12 month price objectives for Mersana Therapeutics' stock. Their MRSN share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.29 in the next year. This suggests a possible upside of 121.3% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2024? Mersana Therapeutics' stock was trading at $2.32 at the start of the year. Since then, MRSN shares have increased by 22.4% and is now trading at $2.84. View the best growth stocks for 2024 here. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). The business had revenue of $10.70 million for the quarter, compared to the consensus estimate of $22.59 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative trailing twelve-month return on equity of 282.36%. The business's revenue was down 27.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.44) EPS. What ETFs hold Mersana Therapeutics' stock? ETFs with the largest weight of Mersana Therapeutics (NASDAQ:MRSN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Tema Oncology ETF (CANC). What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hunter Perkins Capital Management LLC (0.01%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Lawrence M Alleva, Mohan Bala, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRSN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
